Clinical trialPhase 1Recruiting
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 20 November 2024
- Expected end
- May 2027
- Enrollment
- 20 participants
- Sites
- 1
- Primary outcomes
- Primary Endpoint
- Sponsor
- Other
- Results posted
- No
- Last update
- 19 December 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- BackgroundFirst-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diver… DOI 10.1158/1078-0432.ccr-14-3321↗
- BackgroundProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the Un… DOI 10.1158/0008-5472.can-14-0155↗